MMP14 expression and collagen remodelling support uterine leiomyosarcoma aggressiveness
Molecular Oncology · 2024
DOI: 10.1002/1878-0261.13440 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Jordi Gonzalez-Molina und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Leiomyosarcoma, Uterine Neoplasms, Carcinoma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Barncancerfonden, Cancerfonden, Kreftforeningen.
Abstract (Originalsprache)
Fibrillar collagen deposition, stiffness and downstream signalling support the development of leiomyomas (LMs), common benign mesenchymal tumours of the uterus, and are associated with aggressiveness in multiple carcinomas. Compared with epithelial carcinomas, however, the impact of fibrillar collagens on malignant mesenchymal tumours, including uterine leiomyosarcoma (uLMS), remains elusive. In this study, we analyse the network morphology and density of fibrillar collagens combined with the gene expression within uLMS, LM and normal myometrium (MM). We find that, in contrast to LM, uLMS tumours present low collagen density and increased expression of collagen‐remodelling genes, features associated with tumour aggressiveness. Using collagen‐based 3D matrices, we show that matrix metalloproteinase‐14 (MMP14), a central protein with collagen‐remodelling functions that is particularly overexpressed in uLMS, supports uLMS cell proliferation. In addition, we find that, unlike MM and LM cells, uLMS proliferation and migration are less sensitive to changes in collagen substrate stiffness. We demonstrate that uLMS cell growth in low‐stiffness substrates is sustained by an enhanced basal yes‐associated protein 1 (YAP) activity. Altogether, our results indicate that uLMS cells acquire increased collagen remodelling capabilities and are adapted to grow and migrate in low collagen and soft microenvironments. These results further suggest that matrix remodelling and YAP are potential therapeutic targets for this deadly disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
- Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
- Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
- Department of Cellular Biology and Genetics, Federal University of Rio Grande do Norte, Natal, Brazil.
- Department of Biomedical Laboratory Science, Norwegian University of Science and Technology, Trondheim, Norway.
ORCID-Profile: Jordi Gonzalez-Molina, Paula Hahn, Okan Gultekin, Kaisa Lehti, Joseph W Carlson
Förderung
- Barncancerfonden
- Cancerfonden
- Kreftforeningen
- Vetenskapsrådet
Zitieren
APA
Gonzalez-Molina, J., Hahn, P., Falcão, R. M., Gultekin, O., Kokaraki, G., Zanfagnin, V., Braz Petta, T., Lehti, K., & Carlson, J. W. (2024). MMP14 expression and collagen remodelling support uterine leiomyosarcoma aggressiveness. Molecular Oncology. https://doi.org/10.1002/1878-0261.13440
Vancouver
Gonzalez-Molina J, Hahn P, Falcão RM, Gultekin O, Kokaraki G, Zanfagnin V, et al. MMP14 expression and collagen remodelling support uterine leiomyosarcoma aggressiveness. Molecular Oncology. 2024. doi:10.1002/1878-0261.13440
BibTeX
@article{GonzalezMolina2024,
author = {Gonzalez-Molina, Jordi and Hahn, Paula and Falcão, Raul Maia and Gultekin, Okan and Kokaraki, Georgia and Zanfagnin, Valentina and Braz Petta, Tirzah and Lehti, Kaisa and Carlson, Joseph W},
title = {MMP14 expression and collagen remodelling support uterine leiomyosarcoma aggressiveness},
journal = {Molecular Oncology},
year = {2024},
doi = {10.1002/1878-0261.13440}
}
EUVIMED